Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Adenoviral infectivity of exfoliated viable cells in urine: implications for the detection of bladder cancer.

Murali A, Kasman L, Voelkel-Johnson C.

BMC Cancer. 2011 May 12;11:168. doi: 10.1186/1471-2407-11-168.

2.

[Usefulness of survivin/glyceraldehyde-3-phosphate dehydrogenase ratio in urine exfoliated cells for the detection of bladder tumor].

Sakamoto Y, Nishioka J, Noma K, Yasuda K, Nakatani K, Kise H, Sugimura Y, Nobori T.

Rinsho Byori. 2011 May;59(5):446-51. Japanese.

PMID:
21706857
3.

Development of replication-competent adenovirus for bladder cancer by controlling adenovirus E1a and E4 gene expression with the survivin promoter.

Seo HK, Seo JB, Nam JK, Jeong KC, Shin SP, Kim IH, Lee SD, Lee SJ.

Oncotarget. 2014 Jul 30;5(14):5615-23.

4.

Survivin-responsive conditionally replicating adenovirus kills rhabdomyosarcoma stem cells more efficiently than their progeny.

Tanoue K, Wang Y, Ikeda M, Mitsui K, Irie R, Setoguchi T, Komiya S, Natsugoe S, Kosai K.

J Transl Med. 2014 Jan 27;12:27. doi: 10.1186/1479-5876-12-27.

5.

Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer.

Zhu HJ, Zhang ZQ, Zeng XF, Wei SS, Zhang ZW, Guo YL.

Cancer Gene Ther. 2004 Apr;11(4):263-72.

PMID:
14963492
6.

The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.

Peng XY, Won JH, Rutherford T, Fujii T, Zelterman D, Pizzorno G, Sapi E, Leavitt J, Kacinski B, Crystal R, Schwartz P, Deisseroth A.

Cancer Res. 2001 Jun 1;61(11):4405-13.

7.

Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.

Wang R, Wang X, Li B, Lin F, Dong K, Gao P, Zhang HZ.

Breast Cancer Res Treat. 2009 Sep;117(1):45-54. doi: 10.1007/s10549-008-0163-6.

PMID:
18791823
8.

Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.

Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, Barker S, Yamaoto M, Li F, Alvarez RD, Curiel DT.

Cancer Gene Ther. 2004 Apr;11(4):256-62.

PMID:
15017380
9.

[Gene therapy study on bladder cancer with recombinant adenoviral vector carrying LRIG1 gene driven by Survivin promoter].

Yan ZJ, Cheng Y, Jiang JH, Hu JS, Shi XD.

Zhonghua Wai Ke Za Zhi. 2012 Aug;50(8):732-6. Chinese.

PMID:
23157908
10.

A novel gene expression system for detecting viable bladder cancer cells.

Ueki H, Watanabe M, Kaku H, Huang P, Li SA, Ochiai K, Hirata T, Noguchi H, Yamada H, Takei K, Nasu Y, Kashiwakura Y, Kumon H.

Int J Oncol. 2012 Jul;41(1):135-40. doi: 10.3892/ijo.2012.1417.

PMID:
22470055
11.

Noninvasive detection of bladder cancer in an orthotopic murine model with green fluorescence protein cytology.

Tanaka M, Gee JR, De La Cerda J, Rosser CJ, Zhou JH, Benedict WF, Grossman HB.

J Urol. 2003 Sep;170(3):975-8.

PMID:
12913753
12.

Specific survivin dual fluorescence resonance energy transfer molecular beacons for detection of human bladder cancer cells.

Wang ZQ, Zhao J, Zeng J, Wu KJ, Chen YL, Wang XY, Chang LS, He DL.

Acta Pharmacol Sin. 2011 Dec;32(12):1522-8. doi: 10.1038/aps.2011.122.

13.

A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.

Li B, Liu X, Fan J, Qi R, Bo L, Gu J, Qian Q, Qian C, Liu X.

J Gene Med. 2006 Oct;8(10):1232-42.

PMID:
16900558
14.

The value of combined use of survivin mRNA and matrix metalloproteinase 2 and 9 for bladder cancer detection in voided urine.

Eissa S, Badr S, Elhamid SA, Helmy AS, Nour M, Esmat M.

Dis Markers. 2013;34(1):57-62. doi: 10.3233/DMA-2012-0923.

15.

Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection.

Park HS, Park WS, Bondaruk J, Tanaka N, Katayama H, Lee S, Spiess PE, Steinberg JR, Wang Z, Katz RL, Dinney C, Elias KJ, Lotan Y, Naeem RC, Baggerly K, Sen S, Grossman HB, Czerniak B.

J Natl Cancer Inst. 2008 Oct 1;100(19):1401-11. doi: 10.1093/jnci/djn304. Erratum in: J Natl Cancer Inst. 2008 Dec 3;100(23):1740.

16.
17.

Epigenetic alterations of adenomatous polyposis coli (APC), retinoic acid receptor beta (RARĪ²) and survivin genes in tumor tissues and voided urine of bladder cancer patients.

Berrada N, Amzazi S, Ameziane El Hassani R, Benbacer L, El Mzibri M, Khyatti M, Chafiki J, Abbar M, Al Bouzidi A, Ameur A, Attaleb M.

Cell Mol Biol (Noisy-le-grand). 2012 Sep 10;Suppl.58:OL1744-51.

PMID:
22992440
18.

Urine detection of survivin and diagnosis of bladder cancer.

Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC.

JAMA. 2001 Jan 17;285(3):324-8.

PMID:
11176843
19.

Histone deacetylase inhibition enhances adenoviral vector transduction in inner ear tissue.

Taura A, Taura K, Choung YH, Masuda M, Pak K, Chavez E, Ryan AF.

Neuroscience. 2010 Apr 14;166(4):1185-93. doi: 10.1016/j.neuroscience.2009.12.064.

20.

Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer.

Moussa O, Abol-Enein H, Bissada NK, Keane T, Ghoneim MA, Watson DK.

J Urol. 2006 Jun;175(6):2312-6.

PMID:
16697865

Supplemental Content

Support Center